Ashley Gallagher, Associate Editor

McKesson ideaShare is held from June 22 to June 25 in Las Vegas, Nevada.

In 2018, brentuximab vedotin was approved for advanced Hodgkin lymphoma based on an improvement in progression-free survival of 82.3% in combination with chemotherapy.

A counterfeit medication was reportedly purchased at a retail pharmacy, appearing to have contained another type of diabetes medication that led to an adverse reaction.

Investigators found that individuals who received metformin were approximately 40% less likely to develop long COVID than those who received a placebo.

Trial results demonstrated that 58.5% of individuals receiving luspatercept-aamt (Reblozyl; Bristol Myers Squibb) achieved the primary endpoint of red blood cell transfusion independence of at least 12 weeks.

Study investigators said that understanding how the human immune response relates to respiratory syncytial virus infection has been a major obstacle for vaccine development.

Study evaluates the interaction between excessive salt intake and hypertension, cognitive dysfunction, and dementia.

Additionally, data from the SCARLET trial presented at ASCO 2023 indicate the safety and efficacy of sotorasib in combination with platinum-based chemotherapy treating non¬–small cell lung cancer.

Investigators of the study aimed to determine whether the analytical performance specifications of 24,25(OH)2D could be generated.

The CDC has recommended a follow-up nucleic acid amplification test to be used for patients clinically suspected to have influenza, despite a negative POC test.

Investigators from the Barts Cancer Institute discovered that AMP-activated protein kinase is an essential sensor for tumor dissemination.

Positive data from the phase 3 A DUE study demonstrated that the investigational combination therapy of macitentan 10 mg and tadalafil 40 in a single tablet improved pulmonary hemodynamics compared to the same drugs as monotherapies.

Previously, upadacitinib improved symptoms through 2 years in the SELECT-PsA 1 trial for those with psoriatic arthritis with prior inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug.

Trial results support 5.4 mg/kg of trastuzumab deruxtecan as the optimal dose in individuals with HER2+ metastatic colorectal cancer.

The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.

Nivolumab plus ipilimumab combination improved overall survival, with 21% of individuals with metastatic non–small cell lung cancer treated with the combination and 2 cycles of chemotherapy alive compared to 16% with chemotherapy alone.

Ribociclib (Kisqali) demonstrated a 26% risk reduction in distant disease-free survival and a 28% risk reduction in recurrence-free survival in patients with HR+/HER2- early breast cancer.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.

Investigators found thinner ventricular walls, disorganized and ruptured myocardial fiber, mild inflammatory infiltration, and mild epicardia or interstitial fibrosis in the hearts of mice infected with COVID-19.

In the initial cohort, 63% of patients with advanced melanoma achieved an objective response rate, including 6 who had a complete response and 19 who had a partial response to the combination of fianlimab and cemiplimab.

Individuals administered oral semaglutide 50 mg achieved a statistically significant weight loss of approximately 17.4% after 68 weeks, according to Novo Nordisk.

This marks the fourth drug, and first oral antiviral pill, approved by the FDA to treat adults with mild-to-moderate COVID-19.

It is the second anti-TNFα biosimilar approved for use in the US.

Acinetobacter are gram-negative human pathogens that infect individuals who are critically ill, which can result in severe pneumonia and bloodstream infections.

The use of semaglutide for adolescents was included in recent pediatric guidelines, though there are few studies assessing the drug in this patient population.

Hispanic communities are more likely to use telehealth services, whereas non-Hispanic Black individuals continue to show telehealth inequities.

In a single-center study, investigators reviewed charts of 25 children with inflammatory bowel disease transitioning from infliximab to the biosimilar infliximab-dyyb for maintenance.

The drug is available in 2 formulations, including a weekly injection with a lower dose than previously available as well as a monthly injection.

The attitudes of community-based opioid use disorder treatment center staff toward the emergency department as a site of initiation were varied, with some feeling that emergency department-initiated buprenorphine may attract patients who were not experiencing life-threatening emergencies.

Adalimumab-adbm (Cyltezo Pen; Boehringer Ingelheim) is approved by the FDA as an interchangeable biosimilar to Humira.